Qingshan Li - Publications

Hyperthermia sensitizes cervical cancer to chemoradiotherapy by downregulating c-Myc/WSB1/β-catenin expression.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group

Published: September 07, 2026

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial.

Journal: JAMA oncology

Published: April 30, 2026

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Journal: BMJ (Clinical research ed.)

Published: March 12, 2026

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 05, 2025

Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 22, 2025

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Journal: Nature communications

Published: April 21, 2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: March 27, 2025

Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: December 25, 2024

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Journal: Cell reports. Medicine

Published: December 18, 2024

A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.

Journal: Future oncology (London, England)

Published: December 04, 2024

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: September 29, 2024

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Journal: Lancet (London, England)

Published: August 28, 2024